Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
NCT ID: NCT01233544
Last Updated: 2016-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
300 participants
INTERVENTIONAL
2010-09-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary end point is local progression free survival.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma
NCT04434989
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
NCT04020276
RFA vs. SBRT for Small HCC
NCT03898921
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
NCT04242342
The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
NCT03143140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stereotactic body radiation therapy
Colorectal liver metastases treated by SBRT
SBRT or RFA
Patients are allocated to one of the two arms in a 1:1 randomization
Radiofrequency ablation
Colorectal liver metastases treated by RFA
SBRT or RFA
Patients are allocated to one of the two arms in a 1:1 randomization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SBRT or RFA
Patients are allocated to one of the two arms in a 1:1 randomization
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Liver metastases
* Inoperable (technical or medical)
* 1-4 metastases
* Maximum 40 mm in diameter
* Suitable for both therapies, RFA and SBRT
Exclusion Criteria
* Liver cirrhosis
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Center for Interventional Research in Radiation Oncology (CIRRO)
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Morten Høyer, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus C, , Denmark
Karolinska Institute, Huddinge
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Centre for Interventional Research in Radiation Oncology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RAS 01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.